Lundbeck-partnered preclinical biotech nabs Series A from AstraZeneca

Cambridge, MA biotech Rgenta Therapeutics has secured $52 million in a Series A to take oral small molecules into the clinic.

The 20-person biotech, which is already allied with Lundbeck, looks to ink more pharma partnerships within its core areas of oncology and neuroscience rare diseases, as well as in other disease areas the startup thinks the RNA-targeting platform can go, CSO Travis Wager told Endpoints News ahead of the Tuesday morning news.